All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
Herve Ghesquieres from Hospices Civil de Lyon and University Claude Bernard Lyon 1, along with colleagues, recently published in Annals of Oncology the results of a phase II trial investigating the efficacy of lenalidomide in combination with rituximab in relapsed or refractory (R/R) primary central nervous system lymphoma (PCNSL) patients.
In this open-label, multicenter, singe-arm, prospective, phase II trial the efficacy of intravenous rituximab together with lenalidomide (R2) was assessed in diffuse large B-cell lymphoma (DLBCL)-PCNSL patients and in primary intraocular lymphoma patients. The primary endpoint of this study was overall response rate (ORR). Secondary endpoints included, progression-free survival (PFS), overall survival (OS), and safety.
R2 in R/R DLBCL-PCNSL patients showed promising activity. Nevertheless, further studies are needed to validate these results as the possibility that R2 together with MTX-based chemotherapy might present a good first-line regimen for PCNSL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox